(Q51929379)

17 April 2018

title

Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. (English)

1 reference

17 April 2018

1 reference

3

1 reference

17 April 2018

June-Key Chung

6

object named as

June-Key Chung

1 reference

17 April 2018

author name string

Hyun Hoon Chung

1

1 reference

17 April 2018

Won Jun Kang

2

1 reference

17 April 2018

Noh-Hyun Park

4

1 reference

17 April 2018

Yong-Sang Song

5

1 reference

17 April 2018

Soon-Beom Kang

7

1 reference

17 April 2018

Hyo-Pyo Lee

8

1 reference

17 April 2018

publication date

7 November 2006

1 reference

17 April 2018

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

17 April 2018

volume

34

1 reference

17 April 2018

issue

4

1 reference

17 April 2018

page(s)

480-486

1 reference

17 April 2018

https://scigraph.springernature.com/pub.10.1007/s00259-006-0260-x

exact match

0 references

cites work

Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid

1 reference

https://api.crossref.org/works/10.1007%2FS00259-006-0260-X

Clinical value of positron emission tomography with FDG for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-006-0260-X

Application of oral contrast media in coregistered positron emission tomography-CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-006-0260-X

Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-006-0260-X

Combined PET/CT Imaging in Oncology. Impact on Patient Management

21 January 2018

1 reference

12 December 2020

PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients

1 reference

12 December 2020

PET imaging in gynecologic malignancies

1 reference

12 December 2020

Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.

1 reference

12 December 2020

A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography

1 reference

12 December 2020

Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer

1 reference

12 December 2020

Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer

1 reference

12 December 2020

Image analysis in patients with cancer studied with a combined PET and CT scanner

1 reference

12 December 2020

Imaging of ovarian cancer

1 reference

12 December 2020

Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose

1 reference

12 December 2020

Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG)

1 reference

12 December 2020

Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review

1 reference

12 December 2020

Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.

1 reference

12 December 2020

Clinical Impact of 18F-FDG-PET in the Suspicion of Recurrent Ovarian Carcinoma Based on Elevated Tumor Marker Serum Levels

1 reference

12 December 2020

The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study.

1 reference

12 December 2020

CT and MRI of ovarian cancer

1 reference

12 December 2020

Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT.

1 reference

12 December 2020

Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker

1 reference

12 December 2020

Oral contrast agents in CT of the abdomen

1 reference

12 December 2020

Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma

1 reference

12 December 2020

Peritoneal metastases: detection with spiral CT in patients with ovarian cancer

1 reference

12 December 2020

Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation

1 reference

12 December 2020

Correction for oral contrast artifacts in CT attenuation-corrected PET images obtained by combined PET/CT.

1 reference

12 December 2020

[18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma

1 reference

12 December 2020

Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy

1 reference

12 December 2020

Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.

1 reference

12 December 2020

The role of CT in the evaluation of ovarian malignancy

1 reference

12 December 2020

PET-CT in recurrent ovarian cancer: initial observations

1 reference

12 December 2020

Positron emission tomography scanning: current and future applications

1 reference

12 December 2020

Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report

1 reference

12 December 2020

10.1007/S00259-006-0260-X

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018